About the Company
Ginkgo Bioworks is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021.
Exchange
NYSE
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $DNA News
Ginkgo Bioworks Holdings Inc
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
What's Going On With Ginkgo Bioworks Stock?
Ginkgo Bioworks Holdings, Inc. (NASDAQ:DNA) shares are volatile Thursday. The company announced the acquisition of AgBiome’s ...
Ginkgo to fold AgBiome microbial strain library into its West Sacramento AgBio center
Ginkgo Bioworks said it will combine genetic assets it acquired from AgBiome into its biologics center in 200,000 square feet ...
Ginkgo Bioworks Holdings Inc (DNA) Stock: Tracking the Weekly Performance
Based on Ginkgo Bioworks Holdings Inc (DNA), the company’s capital structure generated 0.18 points at debt to capital in total, while cash flow to debt ratio is standing at -1.18. The debt to equity ...
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q4 2023 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. reports earnings inline with expectations. Reported EPS is $-0.09 EPS, expectations were $-0.09. Ginkgo Bioworks Holdings, Inc. isn’t one of the 30 most popular ...
Ginkgo Bioworks gets grant for gene therapy composition for treating NPC1 using AAV vectors
Discover how Ginkgo Bioworks' patent for gene therapy using AAV vectors could revolutionize NPC1 treatment. Learn more about this groundbreaking technology now!
Ginkgo Bioworks Holdings Inc
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Ginkgo Bioworks Holdings, Inc. Class A
Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial ...
Ginkgo Bioworks Holdings Inc.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Ginkgo Bioworks Holdings Inc. Wt
No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...
Loading the latest forecasts...